Healio

96% of patients with PAH prefer a single-tablet combination therapy

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
The American Journal of Managed Care

Single-Tablet Bictegravir/Lenacapavir Effective After Treatment Switch

ARTISTRY-1 trial showed BIC/LEN is effective in maintaining viral suppression in HIV patients previously on complex ART regimens. BIC/LEN offers a single-tablet alternative for patients with drug-drug ...
Seeking Alpha

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis ...
Monthly Prescribing Reference

Single-Tablet Bictegravir/Lenacapavir Noninferior to Multi-Pill HIV-1 Regimens

Results from ARTISTRY trials will be submitted to regulatory agencies for review. Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an ...
Seeking Alpha

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses ...